Protective effect of ulinastatin on cisplatin-induced toxicity in the kidney epithelial cell line, LLC-PK1

Toxicology Methods

Volumn 9, Issue 1, 1999, Pages 1-10

  Okuda, Masahiro ^a   Takashima, Ayako ^a   Tsuda, Katsuyasu ^a   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cisplatin; Kidney epithelial cells; LLC PK1; Nephrotoxicity; Ulinastatin

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOSPORIN A; GENTAMICIN; LACTATE DEHYDROGENASE; MEMBRANE ENZYME; ULINASTATIN; URANYL NITRATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFECT; ENZYME RELEASE; HUMAN; HUMAN CELL; KIDNEY CELL; KIDNEY HOMOGENATE; NEPHROTOXICITY; PRIORITY JOURNAL;

EID: 0033024713     PISSN: 10517235     EISSN: None     Source Type: Journal    
DOI: 10.1080/105172399242771     Document Type: Article

References (23)

1. Astrup T, Nissen U. Urinary trypsin inhibitor (mingin): transformation into a new trypsin inhibitor by acid hydrolysis or by sialidase. Nature. 1964;4942:255-257.
2. Faarvang HJ, Knudsen PJ. Hyaluronidase inhibitor and trypsin inhibitor in preparations from human urine. Proc Soc Exp Biol Med. 1961;108:591-592.
3. Sumi H, Minakata K, Takada Y, Takada A. Trypsin inhibitors in human urine. J Physiol Soc (Jpn). 1977;39:53-58.
4. Jönsson-Berling B-M, Ohlsson K. Distribution and elimination of intravenously injected urinary trypsin inhibitor. Scand J Clin Lab Invest. 1991;51:549-557.
5. Kudo Y, Egashira T, Yamanaka Y. Protective effect of ulinastatin against liver injury caused by ischemia-reperfusion in rats. Jpn J Pharmacol. 1992;60:239-245.
6. Li X-K, Suzuki H, Kimura T, Kawabe A, Uno T, Harada Y. Ulinastatin, a protease inhibitor, attenuates intestinal ischemia/reperfusion injury. Transplant Proc. 1994;26:2423-2425.
7. 2) poisoning. Nephron. 1991;58:300-305.
8. Umeki S, Tsukiyama K, Okimoto N, Soejima R. Urinastatin (kunitz-type proteinase inhibitor) reducing cisplatin nephrotoxicity. Am J Med Sci. 1989;298:221-226.
9. 1. In Vitro (Rockville). 1976;12:670-677.
10. +-dependent hexose transport in a cultured cell line of porcine kidney cells. Am J Physiol. 1982;242:C94-C101.
11. 1). Biochim Biophys Acta. 1984;769:514-518.
12. 1): a model system for aminoglycoside nephrotoxicity. J Pharmacol Exp Ther. 1984;230:742-748.
13. 1 ). J Pharmacol Exp Ther. 1988;247:349-354.
14. 1). Am J Physiol. 1988;254:C251-C257.
15. 1 cells. Pharm Res. 1994;11:609-615.
16. Scoble JE, Senior JCM, Chan P, Varghese Z, Sweny P, Moorhead JF. In vitro cyclosporin toxicity: the effect of verapamil. Transplantation. 1989;47:647-650.
17. 1 cells as a model for cis-diamminedichloroplatinum(II) nephrotoxicity and modulation by thiol rescue agents. Cancer Res. 1988;48:6017-6024.
18. Inui K, Okano T, Takano M, Kitazawa S, Hori R. A simple method for the isolation of basolateral plasma membrane vesicles from rat kidney cortex. Biochim Biophys Acta. 1981;647:150-154.
19. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
20. Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW. Mechanism of cis-platinum nephrotoxicity: II. morphologic observations. J Pharmacol Exp Ther. 1980;213:551-556.
21. Jones BR, Bhalla RB, Mladek J, et al. Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clin Pharmacol Ther. 1980;27:557-562.
22. 1. Eur J Physiol. 1996;433:9-15.
23. Yamasaki F, Ishibashi M, Nakakuki M, Watanabe M, Shinkawa T, Mizota M. Protective action of ulinastatin against cisplatin nephrotoxicity in mice and its effect on the lysosomal fragility. Nephron. 1996;74:158-167.